Vaccine adjuvants revisited

Aguilar, Julio César; Rodríguez, Ernesto Galbán

doi:10.1016/j.vaccine.2007.01.111

Cited by 445 publications

(351 citation statements)

References 101 publications

Supporting

Mentioning

324

Contrasting

Unclassified

Order By: Relevance

“…Vaccine adjuvants are compounds, such as salts, oil emulsions and bacterial components, co-administered with a vaccine to stimulate or amplify the host's immune responses to enhance the immunogenicity of the vaccine antigen. 17,54,[59][60][61] Vaccine adjuvants such as aluminium salts and oil emulsions were heavily studied for use with the parenteral inactivated polio vaccine (IPV), to attempt to reduce vaccine dose and, hence, improve early schedule completion and decrease vaccine costs. 62 However, few adjuvant candidates have been tested for use with live, oral rotavirus vaccines.…”

Section: Rotavirus Vaccine Adjuvantsmentioning

confidence: 99%

Options for improving effectiveness of rotavirus vaccines in developing countries

Tissera

Cowley

Bogdanovic-Sakran

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.

show abstract

Section: Rotavirus Vaccine Adjuvantsmentioning

confidence: 99%

Options for improving effectiveness of rotavirus vaccines in developing countries

Tissera

Cowley

Bogdanovic-Sakran

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…[10,11] Conversely, small and soluble antigens, such as proteins and peptides, are poorly internalized and thus weakly immunogenic; therefore, an adjuvant is needed to intensify the immune response. [12,13] Triggering an efficient immune response to low-molecular-weight compounds 60 (haptens) is an even more challenging task because they are smaller and lack a peptide structure, so they cannot be presented by MHC II molecules unless they are conjugated to proteins prior to immunization. [14,15] One of the emerging strategies for increasing the efficiency of the phagocytosis step, thereby enhancing the antibody response, is the use of nanomaterials that can increase the size of the antigen 65 and modify its surface properties.…”

Section: Introductionmentioning

confidence: 99%

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

Parra

Abad‐Somovilla

Mercader

et al. 2013

Journal of Controlled Release

View full text Add to dashboard Cite

Carbon nanotubes (CNTs) are nanomaterials with interesting emerging applications. Their 25 properties makes CNTs excellent candidates for use as new nanovehicles in drug delivery, immunization and diagnostics. In the current study, we assessed the immune-response-amplifying properties of CNTs to haptens by using azoxystrobin, the first developed strobilurin fungicide, as a model analyte. An azoxystrobin derivative bearing a carboxylated spacer arm (hapten AZc6) was covalently coupled to bovine serum albumin (BSA), and the resulting BSA-AZc6 conjugate was 30 covalently linked to four functionalized CNTs of different shapes and sizes, varying in diameter and length. These four types of CNT-based constructs were obtained using efficient, fast, and easy functionalization procedures based on microwave-assisted chemistry. New Zealand rabbits and BALB/c mice were immunized with BSA-AZc6 alone and with the four CNT-BSA-AZc6 constructs, both with and without Freund's adjuvant. The IgG-type antibody responses were assessed 35 in terms of the titer and affinity, paying special attention to the relationship between the immune response and the size and shape of the employed CNTs. Immunization with CNT-BSA-AZc6 resulted in enhanced titers and excellent affinities for azoxystrobin. More important, remarkable IgG responses were obtained even in the absence of an adjuvant, thus proving the self-adjuvanting capability of CNTs. Immunogens were able to produce strong anti-azoxystrobin immune responses 40 in rabbits even when administered at a BSA-AZc6 conjugate dose as low as 0.05 g. The short and thick CNT-BSA-AZc6 construct produced the best antibody response under all tested conditions.

show abstract

“…To boost the immune response of the vertebrate, antigens are usually inoculated in conjunction with adjuvants. The mechanisms by which adjuvants improve the immune response are still poorly understood (Singh & O'Hagan 1999;Aguilar & Rodriguez 2007). The specific antibodies produced against pathogen and/or vector antigens will interfere with the development of the pathogen within the vector following a blood meal on a vaccinated and infected individual.…”

Section: Transmission-blocking Vaccines (Tbvs)mentioning

confidence: 99%

Transgenesis, Paratransgenesis and Transmission Blocking Vaccines to Prevent Insect-Borne Diseases

Ramalho-Ortigão¹,

Coutinho-Abreu²

2012

Integrated Pest Management and Pest Control - Current and Future Tactics

View full text Add to dashboard Cite

Vaccine adjuvants revisited

Cited by 445 publications

References 101 publications

Options for improving effectiveness of rotavirus vaccines in developing countries

Options for improving effectiveness of rotavirus vaccines in developing countries

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

Transgenesis, Paratransgenesis and Transmission Blocking Vaccines to Prevent Insect-Borne Diseases

Contact Info

Product

Resources

About